Domain's $760 million co-investment partnership with Rusnano bears fruit with fifth transaction funded Manufacturing facility in Russia to break ground this year, seeks to license rights from additional emerging pharma companies
July 29, 2013ReVision Optics, has received funding under Domain's investment agreement with Rusnano. In addition, NovaMedica, the manufacturing facility in Russia to break ground this year, seeks to license rights from additional emerging pharma companies.
More »
aTyr Pharma Completes $49 Million Financing to Advance a Therapeutic Pipeline for Rare Autoimmune Diseases from a Newly Discovered Class of Proteins, Physiocrines
July 29, 2013A premier, global public investment fund joined existing investors in the equity financing, which was capped at $49 by aTyr. The financing supports the clinical development of aTyr's first therapeutic program to treat rare autoimmune diseases.
More »
aTyr Pharma Closes $10 Million Venture Debt Loan from Silicon Valley Bank
July 29, 2013In conjunction with a Series D financing, aTyr closed a $10M debt financing from Silicon Valley Bank to support the clinical development of aTyr's first therapeutic program to treat rare autoimmune diseases and a rare disease pipeline in immune disorders.
More »